Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside

Overview

Journal Wiley Interdiscip Rev Nanomed Nanobiotechnol

Specialty Biotechnology

Date 2024 Oct 16

PMID 39407431

Authors

Xiaodan Jiao

Hao Hong

Weibo Cai

Affiliations

Soon will be listed here.

Abstract

In recent years, the application of radionuclides-containing nanomaterials in cancer treatment has garnered widespread attention. The diversity of nanomaterials allows researchers to selectively combine them with appropriate radionuclides for biomedical purposes, addressing challenges faced by peptides, small molecules, or antibodies used for radionuclide labeling. However, with advantages come challenges, and nanoradionuclides still encounter significant issues during clinical translation. This review summarized the recent progress of nanosized radionuclides for cancer treatment or diagnosis. The discussion began with representative radionuclides and the methods of incorporating them into nanomaterial structures. Subsequently, new combinations of nanomaterials and radionuclides, along with their applications, were introduced to demonstrate their future trends. The benefits of nanoradionuclides included optimized pharmacokinetic properties, enhanced disease-targeting efficacy, and synergistic application with other treatment techniques. Besides, the basic rule of this section was to summarize how these nanoradionuclides can truly impact the diagnosis and therapy of various cancer types. In the last part, the focus was devoted to the nanoradionuclides currently applicable in clinics and how to address the existing issues and problems based on our knowledge.

References

Zheng B, Wu Q, Jiang Y, Hou M, Zhang P, Liu M . One-pot synthesis of Ga-doped ultrasmall gold nanoclusters for PET/CT imaging of tumors. Mater Sci Eng C Mater Biol Appl. 2021; 128:112291. DOI: 10.1016/j.msec.2021.112291. View

Garg I, Nathan M, Packard A, Kwon E, Larson N, Lowe V . C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen ≤0.1 ng/ml. J Cancer Res Ther. 2020; 17(2):358-365. DOI: 10.4103/jcrt.JCRT_373_19. View

Wu P, Zhu H, Zhuang Y, Sun X, Gu N . Combined Therapeutic Effects of I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer. Int J Nanomedicine. 2020; 15:2777-2787. PMC: 7185645. DOI: 10.2147/IJN.S215137. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Yuan Y, Zhang J, Qi X, Li S, Liu G, Siddhanta S . Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy. Nat Mater. 2019; 18(12):1376-1383. PMC: 6872935. DOI: 10.1038/s41563-019-0503-4. View

Runge R, Oehme L, Kotzerke J, Freudenberg R . The effect of dimethyl sulfoxide on the induction of DNA strand breaks in plasmid DNA and colony formation of PC Cl3 mammalian cells by alpha-, beta-, and Auger electron emitters (223)Ra, (188)Re, and (99m)Tc. EJNMMI Res. 2016; 6(1):48. PMC: 4893047. DOI: 10.1186/s13550-016-0203-x. View

Luderer M, de la Puente P, Azab A . Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy. Pharm Res. 2015; 32(9):2824-36. DOI: 10.1007/s11095-015-1718-y. View

Dziawer L, Majkowska-Pilip A, Gawel D, Godlewska M, Pruszynski M, Jastrzebski J . Trastuzumab-Modified Gold Nanoparticles Labeled with At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer. Nanomaterials (Basel). 2019; 9(4). PMC: 6523862. DOI: 10.3390/nano9040632. View

Rivera-Gil P, Jimenez de Aberasturi D, Wulf V, Pelaz B, Del Pino P, Zhao Y . The challenge to relate the physicochemical properties of colloidal nanoparticles to their cytotoxicity. Acc Chem Res. 2012; 46(3):743-9. DOI: 10.1021/ar300039j. View

10.

Salvanou E, Stellas D, Tsoukalas C, Mavroidi B, Paravatou-Petsotas M, Kalogeropoulos N . A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225. Pharmaceutics. 2020; 12(2). PMC: 7076693. DOI: 10.3390/pharmaceutics12020188. View

11.

Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F . EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011; 38(7):1393-406. DOI: 10.1007/s00259-011-1812-2. View

12.

Feuerecker B, Biechl P, Seidl C, Bruchertseifer F, Morgenstern A, Schwaiger M . Diverse metabolic response of cancer cells treated with a Bi-anti-EGFR-immunoconjugate. Sci Rep. 2021; 11(1):6227. PMC: 7973706. DOI: 10.1038/s41598-021-84421-4. View

13.

De Ruysscher D, Niedermann G, Burnet N, Siva S, Lee A, Hegi-Johnson F . Radiotherapy toxicity. Nat Rev Dis Primers. 2019; 5(1):13. DOI: 10.1038/s41572-019-0064-5. View

14.

Hong H, Yang K, Zhang Y, Engle J, Feng L, Yang Y . In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano. 2012; 6(3):2361-70. PMC: 3314116. DOI: 10.1021/nn204625e. View

15.

Cedrowska E, Pruszynski M, Majkowska-Pilip A, Meczynska-Wielgosz S, Bruchertseifer F, Morgenstern A . Functionalized TiO nanoparticles labelled with Ac for targeted alpha radionuclide therapy. J Nanopart Res. 2018; 20(3):83. PMC: 5861168. DOI: 10.1007/s11051-018-4181-y. View

16.

Liu H, Ren G, Miao Z, Zhang X, Tang X, Han P . Molecular optical imaging with radioactive probes. PLoS One. 2010; 5(3):e9470. PMC: 2830426. DOI: 10.1371/journal.pone.0009470. View

17.

Berke S, Kampmann A, Wuest M, Bailey J, Glowacki B, Wuest F . F-Radiolabeling and In Vivo Analysis of SiFA-Derivatized Polymeric Core-Shell Nanoparticles. Bioconjug Chem. 2017; 29(1):89-95. DOI: 10.1021/acs.bioconjchem.7b00630. View

18.

Wharton L, Zhang C, Yang H, Zeisler J, Radchenko V, Rodriguez-Rodriguez C . [Bi]Bi/[In]In-neunpa-cycMSH: Theranostic Radiopharmaceutical Targeting Melanoma─Structural, Radiochemical, and Biological Evaluation. Bioconjug Chem. 2022; 33(3):505-522. DOI: 10.1021/acs.bioconjchem.2c00038. View

19.

Kato H, Huang X, Kadonaga Y, Katayama D, Ooe K, Shimoyama A . Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy. J Nanobiotechnology. 2021; 19(1):223. PMC: 8317303. DOI: 10.1186/s12951-021-00963-9. View

20.

Morris M, Corey E, Guise T, Gulley J, Kelly W, Quinn D . Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019; 16(12):745-756. PMC: 7515774. DOI: 10.1038/s41585-019-0251-x. View